Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal

Similar documents
10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

Northwestern Polytechnic University

2017/2018 Annual Volunteer Tuberculosis Notice

Revised Technical Instructions for Civil Surgeons. October 9, 2018

Santa Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

Please distribute a copy of this information to each provider in your organization.

MEMORANDUM. Re: Guidance for follow-up of newly-arrived individual with Class B1 Tuberculosis Pulmonary Tuberculosis, no treatment

TUBERCULOSIS CONTACT INVESTIGATION

LATENT TUBERCULOSIS. Robert F. Tyree, MD

Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines

Why need to havetb Clearance. To Control and Prevent Tuberculosis

Contact Investigation and Prevention in the USA

MEMORANDUM. Re: Guidance for follow-up of newly-arrived Individual with a Class B1 Tuberculosis Extrapulmonary Tuberculosis

Diagnosis and Medical Management of Latent TB Infection

A Mobile Health Intervention Utilizing Community Partnership to Improve Access to Latent Tuberculosis Infection Treatment

Tuberculosis: A Provider s Guide to

Tuberculosis Populations at Risk

TB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

TB Infection Who is Testing and Treating? TB Control and Elimination: Current Dilemma. Span of TB Control: 2010

INDEX CASE INFORMATION

17-ID-09. Title: Establishing a Case Definition for Latent TB Infection (TB Infection)

Tuberculosis Tools: A Clinical Update

Tuberculosis Screening Protocol For Use In Marin County School Settings

Diagnosis Latent Tuberculosis. Disclosures. Case

LTBI: Who to Test & When to Treat

Contact Investigation

Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges

Tuberculosis Screening and Targeted Testing of College and University Students: Developing a Best Practice Approach:

Latent Tuberculosis Best Practices

Table 9. Policy for Tuberculosis Surveillance and Screening

TB-Free California: How close are we? How can we get closer?

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

Approaches to LTBI Diagnosis

2016 Annual Tuberculosis Report For Fresno County

Management of Pediatric Tuberculosis in New Jersey

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University

UC DavisTB Screening Requirement: How to submit your TB Health Assessment Form

Tuberculosis in Chicago 2007

Latent tuberculosis infection

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

Monitoring & evaluation LTBI management in the Netherlands. Key lessons.

Communicable Disease Control Manual Chapter 4: Tuberculosis. Assessment and Follow-Up of TB Contacts

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Peggy Leslie-Smith, RN

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of

Tuberculosis: Where Are We Now?

Diagnosis and Treatment of Tuberculosis, 2011

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

The Epidemiology of Tuberculosis in Minnesota,

TB Intensive Minneapolis, Minnesota September 23-26, 2008

State of the State in TB Control

Latent TB, TB and the Role of the Health Department

SCHOOL OF MEDICINE IMMUNIZATION COMPLIANCE FORM

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]

TB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009

ATTACHMENT 2. New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS

LTBI monitoring and evaluation in the Netherlands

TUBERCULOSIS CONTACT INVESTIGATION

Fundamentals of Tuberculosis (TB)

Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Communicable Disease Control Manual Chapter 4: Tuberculosis

TB in Corrections Phoenix, Arizona

LATENT TUBERCULOSIS SCREENING AND TREATMENT:

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

TB Contact Investigation Basics

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis?

ANNUAL TUBERCULOSIS REPORT OREGON Oregon Health Authority Public Health Division TB Program November 2012

TB in Corrections Phoenix, Arizona

Director, University Health Services. Medical Director

TB EPIDEMIOLOGY. Outline. Estimated Global TB Burden, TB epidemiology

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

Tuberculosis Epidemiology

2014 Annual Report Tuberculosis in Fresno County. Department of Public Health

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TB in the Patient with HIV

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016

The Public Health Impact of TB in the Correctional System. Sarah Bur, RN, MPH Federal Bureau of Prisons Infection Prevention and Control Officer

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents

TB Contact Investigation

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

Screening and Treatment Recommendations for Persons Exposed to MDR TB

Guidance for Identifying Risk Factors for Mycobacterium tuberculosis (MTB) During Evaluation of Potential Living Kidney Donors

Tuberculosis Elimination Jennifer Flood, MD, MPH Pennan Barry, MD, MPH NAR-NTCA February 25, 2016

LTBI Treatment and Anti TNF alpha

has the following disclosures to make:

DENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

Proposed Regs.pdf

Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)

Contact Investigation San Antonio, Texas January 14-15, 2013

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

TB in Foreign Born and High Risk Populations

Tuberculosis in Pregnancy

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

Transcription:

Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal Civil surgeons are required to report tuberculosis (TB) screening outcomes that result in latent TB infection (LTBI) diagnosis to public health departments. This document is limited to providing instructions for reporting LTBI in California. Please see the CDC TB Technical Instructions for civil surgeons for details and other requirements. Civil surgeons in California will be reporting to one of 61 Local Health Departments (LHDs) in the state on the basis of patient address. Per the TB technical instructions, notification to the LHD should include patient name, contact information, Interferon Gamma Release Assay (IGRA) and chest x-ray results. Civil surgeons should use the CalREDIE Provider Portal system for reporting to local health department TB programs requesting use of the Provider Portal. CalREDIE is a communicable disease reporting system used by the California Department of Public Health. The Provider Portal feature allows providers to submit necessary patient information and test results electronically to the LHD TB program via a secure web-based interface. Contact LHDs in your service area to determine if the Provider Portal should be used for reporting. Reporting processes may differ by LHD. Visit https://ctca.org/locations.html for a complete list of California s LHD TB programs. Who should be reported? Applicants who meet the following criteria have LTBI and should be reported: Positive IGRA result; and Chest x-ray not suggestive of tuberculosis disease; and No known HIV infection; and No signs or symptoms of TB disease Note: Do not report applicants who have written documentation of completing treatment for LTBI prior to the civil surgeon examination. Applicants who need further evaluation and follow-up for possible active TB disease should be immediately referred to the LHD. Please contact the appropriate LHD (based on the applicant s residence) to determine the referral process. Per the technical instructions, applicants who have the following need further evaluation: Abnormal chest x-ray results suggestive of tuberculosis disease Clinical signs or symptoms suggestive of tuberculosis disease or known HIV infection regardless of IGRA result or chest x-ray findings Extrapulmonary disease regardless of chest x-ray results How to report LTBI using CalREDIE Provider Portal? The following instructions are for civil surgeons who are using CalREDIE Provider Portal to electronically report information on applicants diagnosed with LTBI. The Provider Portal feature for TB reporting has three sections: Patient, Supplemental, and Clinical Info. A. Patient Tab: This section is for providing patient demographic and contact information. The following information should be completed: Disease Being Reported, Last Name, First Name, Gender, Race, Ethnicity, DOB, Patient Address (PO box or law office addresses are not acceptable), Country of Birth, Date of Arrival (initial date arrived in the U.S.), Home Telephone or Cellular Phone, and email. 1

Disease Being Reported Select disease being reported to the LHD. Tuberculosis (Infection/No Disease LTBI TB2) is for reporting LTBI B. Supplemental Tab: This section is optional and may be used for providing notes, but does not require data entry. C. Clinical Info Tab: This section contains TB specific fields for the reporting of patient test results and treatment information. There are 9 sections within the Clinical Info tab: 1. Status 2. Initial Patient Evaluation 3. Skin Test and IGRA 4. Chest Imaging 5. Bacteriology, NAA/PCR Tests 6. Latent TB Infection Treatment Information 7. TB Disease Treatment Information 8. Provider Contact Information 9. Notes 2

1. Status Latent TB Infection, No Disease Select one of the following: LTBI test positive (converter) LTBI test positive (reactor/not known converter) Select LTBI test positive (reactor/not known converter) unless the applicant has a documented negative IGRA within the prior two years. In that case, select LTBI test positive (converter). 2. Initial Patient Evaluation Is This Evaluation Part of an Immigration Screening? Is This Evaluation Part of a Contact Investigation? Does Patient Have Signs/Symptoms Consistent with TB Disease? Risk Assessment: Select Identified TB Risk Factors Civil surgeons reporting outcomes from an applicant s immigration screening must select Yes, Civil Surgeon Exam. Civil surgeons reporting outcomes from an applicant s immigration screening can select No. Select No if active TB disease has been ruled out. If patient has signs/symptoms consistent with TB disease contact the health department to refer for further evaluation. The risk assessment is optional. Civil surgeons may indicate any relevant patient TB risk factors to communicate to the LHD. 3

Born in a country w/elevated TB rate includes any country other than Canada, Australia, New Zealand, or a country in western or northern Europe Foreign travel 1 month in a country w/elevated TB rate same countries noted above Immunosuppression (current or planned) HIV infection, organ transplant recipient, treated with TNF-alpha antagonist (e.g. infliximab, etanercept, others), steroids (equivalent of prednisone 15mg/day for 1 month) or other immunosuppressive medication Close contact to case w/infectious TB disease close contact to someone with infectious disease during lifetime None identified - assessment was done and risk factors were not identified Other, specify - risk factors other than those listed were found; comment in the provided text field 3. Skin Test And IGRA An IGRA is required for screening applicants 2 years and older. Tuberculin Skin Test (TST) cannot be used as a substitute for IGRA testing. TST results are not required to be reported. Please include any prior documented IGRA results by selecting Add. Refer children < 2 years of age to the local health department according to the technical instructions. Do not report TST or IGRA results here unless instructed by the LHD. Interferon Gamma Release Assay Date Collected Interferon Gamma Release Assay IGRA Result Indicate date the IGRA was administered. Indicate result of the IGRA test. Positive person is likely infected with M. tuberculosis. Only positive IGRA results need to be reported. Additionally, prior negative or indeterminate results can be reported, but is not required. Prior documented results can be included by selecting Add. Negative person is unlikely infected with M. tuberculosis. Indeterminate- uncertain if person is infected with M. tuberculosis. 4

Not Done Unknown 4. Chest Imaging Imaging Type Imaging Date Performed Imaging Result Select which one of the following was utilized: CXR (chest x-ray) CT Scan Other Indicate date the imaging was done. Indicate the interpretation of the chest imaging. Normal Abnormal, cavitary* Abnormal, non-cavitary consistent with TB* Abnormal, non-cavitary not consistent with TB Pending *Patients with abnormal imaging results (consistent with TB) should be referred to the local health department and should not be reported as LTBI. 5. Bacteriology, NAA/PCR Tests Leave this section blank if microbiologic testing is not being overseen by the civil surgeon. The following applicants will need further microbiologic testing and evaluation. They must be immediately referred to the local health department to avoid delays in diagnosis and treatment. Applicants with abnormal chest x-ray results suggestive of tuberculosis disease Applicants with clinical signs or symptoms suggestive of tuberculosis disease or known HIV infection regardless of IGRA result or chest radiograph findings Applicants with extrapulmonary disease regardless of chest x-ray results 6. Latent TB Infection (LTBI) Treatment Information In addition to reporting LTBI to the LHD, applicants with LTBI should be offered or referred for LTBI treatment in order to prevent potential future active TB disease. LTBI treatment is not required to complete the status adjustment process. 5

Applicants who have documentation of being diagnosed and completing treatment for LTBI prior to the civil surgeon examination must have a chest x-ray as part of the civil surgeon evaluation. If the chest x-ray is negative and the applicant does not have signs or symptoms of TB disease or known HIV infection, the applicant does not have to be reported to the health department. Check if patient referred to another provider for LTBI treatment LTBI Treatment Start Date LTBI Treatment End Date LTBI Treatment Regimen If Treatment Not Started, Primary Reason Why? If applicant was referred for LTBI treatment, indicate in the check box and leave all other fields in this section blank. Please enter the receiving provider s contact information in the Provider Contact Information section at the bottom of the page. If applicant was referred to their primary care provider for LTBI treatment, enter the provider s name, phone number, address and facility name in the Primary Provider Contact Information section. If applicant was referred to a provider who is not their primary care provider, enter the above mentioned information in the Other Provider Contact Information section. If civil surgeon is overseeing LTBI treatment indicate treatment start date; otherwise leave blank. Leave this field blank. If civil surgeon is overseeing treatment, submit initial Provider Portal report without treatment end date. Coordinate reporting of LTBI treatment completion information directly with LHD once patient completes therapy. Complete if civil surgeon is overseeing LTBI treatment; otherwise leave blank. Indicate one of the following treatment regimens: Isoniazid/Rifapentine (3 months; 3HP) Rifampin (4 months; 4R) Isoniazid (9 months; 9H) Isoniazid (6 months; 6H) Other If other option is selected, specify details in the LTBI Treatment Notes field. If LTBI treatment was offered by civil surgeon but not initiated, indicate reason. If patient was referred for treatment, leave blank. Indicate the patient was referred in the check box. 6

LTBI Treatment notes Include any comments/clarifications about LTBI treatment or referrals. 7. TB Disease Treatment Information Leave this section blank when reporting LTBI. 8. Provider Contact Information Primary Provider Contact Information: Primary Provider Name Primary Provider Facility Name Primary Provider Phone Number Primary Provider Address Other Provider Contact Information: Other Provider Type Other Provider Name Other Provider Facility Name Other Provider Phone Number Other Provider Address If applicant was referred to their primary care provider for LTBI treatment, enter the primary provider s name, phone number, address, and facility name. If applicant was referred for LTBI treatment to a provider who is not their primary care provider, enter provider type, provider s name, phone number, address, and facility name. 9. Notes Include any important patient information or clarifications not captured in other sections here. 7